<DOC>
	<DOCNO>NCT01961271</DOCNO>
	<brief_summary>The purpose study assess efficacy buprenorphine transdermal patch ( Norspan® Sovenor® transdermal patch ) patient chronic non-malignant pain moderate severe intensity due osteoarthritis , rheumatoid arthritis , low back pain joint/muscle pain , adequately respond non-opioid painkiller .</brief_summary>
	<brief_title>Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis , Rheumatoid Arthritis , Joint/Muscle Pain</brief_title>
	<detailed_description>Baseline assessment ( Visit 1 ) include medical history , physical examination , vital sign . At Visit 2 [ 7 day ( ± 3 day ) Visit 1 ] subsequent optional titration visit ( Visit 1 + 42 day ) , patient titrate effective tolerate dose Norspan® Sovenor® transdermal patch continue rescue analgesic , necessary . Titration period dependent time achieve optimal pain control determine investigator . The up-titration regime plan weekly basis . Earlier dose titration ( i.e . minimum 3 day patch application ) permit investigator 's discretion pain uncontrolled . Effective tolerate dose assess data record case report form patient diary . According country label , patient begin treatment Norspan® Sovenor® transdermal patch 5mg up-titrated , necessary , maximum Norspan® Sovenor® transdermal patch 40mg accord country label achieve stable pain control . Patients require oral opioid time study discontinue trial .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Males female age 1880 year ( inclusive ) time recruitment . 2 . Clinical diagnosis osteoarthritis , rheumatoid arthritis , low back pain joint / muscle pain . 3 . Having nonmalignant pain moderate severe intensity require opioid adequate analgesia ( accord local label Norspan® Sovenor® ) . This determine use BS11 score , cutoff point ≥4 . 4 . Patients chronic uncontrolled pain assess require opioid treatment treat opioids ( include tramadol , morphine etc . ) within 4 week study entry . 1 . Pregnant lactating female . 2 . Patients chronic condition ( ) , addition osteoarthritis , require ( ) frequent analgesic treatment ( e.g . frequent headache , frequent migraine , gout ) . 3 . Patients await scheduled operation surgical procedure study period 3 month less postoperative . 4 . Prior history opioids precede 1 month prior study management chronic nonmalignant pain . 5 . Prior history buprenorphine transdermal system use . 6 . Patients history allergic reaction paracetamol/ acetaminophen , NSAIDs and/or opioids . 7 . Patients allergies contraindication transdermal system patch adhesive . 8 . Patients dermatological disorder may problem apply patch rotate patch placement area . 9 . Patients cancer ( except basal cell carcinoma ) history cancer diagnose within five year prior first study visit ( except treat basal cell carcinoma ) . 10 . Patients condition brain tumour , brain injury raise intracranial pressure . 11 . Patients history psychiatric disorder , uncontrollable epilepsy , untreated depression psychiatric disorder type would make participation study unacceptable risk patient . 12 . Patients condition cause poor cognitive function assess participate physician . 13 . Patients history alcohol drug abuse patient demonstrate behaviour suggests dependency drug abuse . 14 . Patients currently take hypnotic central nervous system depressant may pose risk additional central nervous system depression study medication . 15 . Patients currently administer monoamine oxidase inhibitor ( MAOIs ) take MAOIs within 2 week screen . 16 . Patients require dose titration adjuvant analgesic i.e . antidepressant ( e.g . amitriptyline , amoxapine , clomipramine , selective serotonin reuptake inhibitor ( SSRIs ) ) anticonvulsant ( e.g . gabapentin , pregabalin ) . Patients allow enter study long stable dos adjuvant analgesic screen dose adjustment study . 17 . Patients receive steroid treatment ( intraarticular , intramuscular , oral , intravenous , epidural corticosteroid injection ) within 6 week prior clinical study plan steroid treatment clinical study period . 18 . Patients use heat facility ( example : heating lamp , electric blanket , sauna , warm compress , heat saline bath , etc. ) . 19 . Patients wish remove hair grow body surface patch place . 20 . Patients currently disability claim process apply disability claim . 21 . Patients childbearing age planning conceive child study period practice adequate contraception . 22 . Patients know severe hepatic impairment determine liver function test within past one year . 23 . Patients currently participate clinical trial within last 30 day prior study recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Norspan</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>transdermal</keyword>
	<keyword>patch</keyword>
	<keyword>chronic pain</keyword>
	<keyword>non-malignant</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>low back pain</keyword>
	<keyword>joint pain</keyword>
	<keyword>muscle pain</keyword>
	<keyword>opioid</keyword>
	<keyword>analgesic</keyword>
	<keyword>painkiller</keyword>
	<keyword>Mundipharma</keyword>
</DOC>